Skip to main content
Premium Trial:

Request an Annual Quote

Genomics: Mitchell Harris, Gil McVean

Mitchell Harris has joined UK company Genomics as chief strategy officer. He also became a member of the firm's executive leadership team. Harris comes to Genomics from Abcam, where he was global head of emerging business lines. Before that, he was a principal at QuantumBlack, the AI and advanced analytics arm of McKinsey & Company, as well as engagement manager at McKinsey.

In addition, Gil McVean has taken on the role of acting chief operating officer at Genomics, in addition to his post as chief information officer and a member of the executive leadership team.  

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.